Cargando…

Editorial: Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments

Detalles Bibliográficos
Autor principal:	Timofeev, Oleg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385431/ https://www.ncbi.nlm.nih.gov/pubmed/34458155 http://dx.doi.org/10.3389/fonc.2021.740578

Ejemplares similares

Mutant p53 in Cancer Progression and Targeted Therapies
por: Zhu, Gaoyang, et al.
Publicado: (2020)

Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
por: Haupt, Ygal, et al.
Publicado: (2016)

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

Regulation of Mutant p53 Protein Expression
por: Vijayakumaran, Reshma, et al.
Publicado: (2015)

Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
por: Kim, Michael Paul, et al.
Publicado: (2015)

Mutant p53 as a Regulator and Target of Autophagy
por: Shi, Yong, et al.
Publicado: (2021)

Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways
por: Haupt, Sue, et al.
Publicado: (2016)

Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin
por: Therachiyil, Lubna, et al.
Publicado: (2020)

Alterations in Mitochondrial and Endoplasmic Reticulum Signaling by p53 Mutants
por: Giorgi, Carlotta, et al.
Publicado: (2016)

Mutant p53 and ETS2, a Tale of Reciprocity
por: Martinez, Luis Alfonso
Publicado: (2016)

Mutant p53: One, No One, and One Hundred Thousand
por: Walerych, Dawid, et al.
Publicado: (2015)

The Contrived Mutant p53 Oncogene – Beyond Loss of Functions
por: Sabapathy, Kanaga
Publicado: (2015)

Corrigendum: The Contrived Mutant p53 Oncogene – Beyond Loss of Functions
por: Sabapathy, Kanaga
Publicado: (2021)

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile
por: Brown, Kate, et al.
Publicado: (2023)

Amplifying Tumor–Stroma Communication: An Emerging Oncogenic Function of Mutant p53
por: Capaci, Valeria, et al.
Publicado: (2021)

Beyond the Mevalonate Pathway: Control of Post-Prenylation Processing by Mutant p53
por: Borini Etichetti, Carla M, et al.
Publicado: (2020)

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
por: Zhang, Meiqiongzi, et al.
Publicado: (2018)

Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
por: Alvarado-Ortiz, Eduardo, et al.
Publicado: (2021)

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
por: Chasov, Vitaly, et al.
Publicado: (2020)

Role of Sex in the Therapeutic Targeting of p53 Circuitry
por: Mancini, Francesca, et al.
Publicado: (2021)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

Editorial: Personalized immunotherapy for cancer
por: Pasetto, Anna, et al.
Publicado: (2023)

Editorial: Advances in wild type and mutant p53 research in cancer
por: Hernández-de la Cruz, Olga N., et al.
Publicado: (2022)

Mutant p53 and Twist1 Co-Expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer
por: Zhang, Yong-Qu, et al.
Publicado: (2021)

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities
por: Gojo, Johannes, et al.
Publicado: (2020)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
por: Muller, Patricia A.J., et al.
Publicado: (2014)

GOF Mutant p53 in Cancers: A Therapeutic Challenge
por: Dolma, Lobsang, et al.
Publicado: (2022)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Rab11-FIP1/RCP Functions as a Major Signalling Hub in the Oncogenic Roles of Mutant p53 in Cancer
por: von Grabowiecki, Yannick, et al.
Publicado: (2021)

Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
por: Bruno, Tiziana, et al.
Publicado: (2016)

Involvement of Glutathione Depletion in Selective Cytotoxicity of Oridonin to p53-Mutant Esophageal Squamous Carcinoma Cells
por: Li, Yinchao, et al.
Publicado: (2020)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
por: Timofeev, Oleg, et al.
Publicado: (2019)

Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy
por: Timofeev, Oleg, et al.
Publicado: (2021)

Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers
por: Wang, Chen-Yun, et al.
Publicado: (2022)

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells
por: Klemke, Luisa, et al.
Publicado: (2021)

Anticancer effect of Indanone-based thiazolyl hydrazone derivative on p53 mutant colorectal cancer cell lines: An in vitro and in vivo study
por: Narayanan, Silpa, et al.
Publicado: (2022)

Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment
por: Ilhan, Harun, et al.
Publicado: (2022)

Cancer Stemness: p53 at the Wheel
por: Ghatak, Dishari, et al.
Publicado: (2021)

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
por: Fedorova, Olga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g7e9jl5frppub9fbam1ck9n37a